Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a strategic partnership with Japanese pharmaceutical company Eisai (TYO: 4523). This collaboration grants Eisai access to MediTrust Health’s “One-Code Direct Payment-Diversified Payment Platform,” aiming to establish a comprehensive disease service model that encompasses prevention, screening, diagnosis, treatment, and care for patients.
Creating a Seamless Patient Experience
The partnership is designed to align innovative drugs more closely with patient needs and enhance treatment accessibility. By integrating a range of services into a single platform, MediTrust Health and Eisai aim to improve the patient journey, from drug search and medication use to payment, making it more efficient and patient-centric.
MediTrust Health’s Diversified Payment Platform
MediTrust Health’s platform offers a one-stop comprehensive solution for diversified payments throughout the patient’s drug search, medication use, and payment process. It aggregates various payment methods, including Huiminbao, commercial medical insurance, charity drug giveaways, out-of-pocket patient drug payment plans (medication welfare plans), and financial installment payments. This platform is the first to offer over 200 innovative special drugs, including an Alzheimer’s disease (AD) drug, providing patients with a wide range of options for managing their healthcare costs.-Fineline Info & Tech
Leave a Reply